CollPlant explores strategic options as revenue drops following milestone loss
Compartilhar
CollPlant Biotechnologies (NASDAQ:CLGN) initiated a formal review of its strategic alternatives after a sharp contraction in milestone revenue caused its first-quarter sales to drop to near-zero, forcing the company to slash its workforce by half.
